Delcath Systems Inc
NASDAQ:DCTH
Delcath Systems Inc
Revenue
Delcath Systems Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Delcath Systems Inc
NASDAQ:DCTH
|
Revenue
$37.2m
|
CAGR 3-Years
119%
|
CAGR 5-Years
88%
|
CAGR 10-Years
43%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Revenue
$20.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Revenue
$16.7B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Revenue
$22.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Revenue
$42B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Revenue
$8.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
Delcath Systems Inc
Revenue Breakdown
Breakdown by Geography
Delcath Systems Inc
Breakdown by Segments
Delcath Systems Inc
|
Total Revenue:
37.2m
USD
|
|
Hepzato Kit:
32.3m
USD
|
|
Chemosat:
4.9m
USD
|
Delcath Systems Inc
Glance View
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.
See Also
What is Delcath Systems Inc's Revenue?
Revenue
37.2m
USD
Based on the financial report for Dec 31, 2024, Delcath Systems Inc's Revenue amounts to 37.2m USD.
What is Delcath Systems Inc's Revenue growth rate?
Revenue CAGR 10Y
43%
Over the last year, the Revenue growth was 1 702%. The average annual Revenue growth rates for Delcath Systems Inc have been 119% over the past three years , 88% over the past five years , and 43% over the past ten years .
You don't have any saved screeners yet